SerenoCem™ granules in mastoid obliteration surgery: A 2-year follow-up case series of 55 patients to determine the risk of progressive bone resorption
- PMID: 31446670
- DOI: 10.1111/coa.13422
SerenoCem™ granules in mastoid obliteration surgery: A 2-year follow-up case series of 55 patients to determine the risk of progressive bone resorption
References
REFERENCES
-
- Harrison L, Kumar S, Bull M, Hatton PV, Bottrill I, Aldren C. Clinical case series describes a contraindication for SerenoCem GranulesTM in mastoid obliteration: Our experience in sixty-four patients. Clin Otol. 2017;42:1095-1100.
-
- Medicines and Healthcare products Regulatory Agency. Medical device alert: SerenoCem Granules - risk of bone reabsorption around granules; 2016. MDA/2016/013. https://mhra.filecamp.com/public/file/2rrh-fo62n0qq. Accessed August 1, 2018.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical